1 Min Read
June 5 (Reuters) - Amgen Inc:
* Amgen submits regulatory applications for repatha® (evolocumab) cardiovascular outcomes data in US and Europe Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.